MetaCap

Anavex Life Sciences (AVXL) vs Champions Oncology (CSBR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Champions Oncology (CSBR) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 35.9% versus a loss of 81.9%. Over five years, CSBR leads with a -53.0% price change compared with -97.0% for AVXL. Champions Oncology is the larger company by market cap ($60.4 million vs $54.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVXL-81.86%CSBR-35.89%
+70%-10%-89%
Nov 21, 20251 yearNov 20, 2026
AVXL-97.08%CSBR-53.68%
+30%-37%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVXL versus CSBR key metrics
MetricAVXLCSBR
Share price$0.5915$4.34
Market cap$54.83M$60.41M
1-day change-11.39%-1.36%
YTD return-83.38%-37.19%
1-year return-81.86%-35.89%
5-year return-96.96%-52.98%
Forward P/E—43.40
EPS (TTM)$-0.14$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$59.42M
Revenue growth (YoY)—+4.36%
Net income (latest FY)$-46.38M$-1.18M
Gross margin—48.00%
Operating margin—-1.92%
Net margin—-1.98%
52-week high$5.36$8.31
52-week low$0.59$4.34
Distance from 52-week high-88.96%-47.77%
Analyst consensusnone—
Average volume1.15M9.71K
Shares outstanding92.70M13.92M
Employees34214
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CSBR has outperformed AVXL by 46.0 percentage points over the past year.

About Anavex Life Sciences

AVXL stock →

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About Champions Oncology

CSBR stock →

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees

AVXL vs CSBR FAQ

Which is bigger, Anavex Life Sciences or Champions Oncology?

Champions Oncology (CSBR) is larger, with a market capitalization of $60.41M compared with $54.83M for Anavex Life Sciences (AVXL).

Which stock has performed better over the past year, AVXL or CSBR?

CSBR returned -35.89% over the past 12 months, compared with -81.86% for AVXL (price return, excluding dividends). Past performance does not predict future results.

Are Anavex Life Sciences and Champions Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons